REFERENCES
- DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; October 10,2006. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
- Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the Interna-tional AIDS Society-USA Panel. JAMA. 2006;296:827–843
- Gulick RM, Ribaudo HJ, Shikuma CM, et al Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850–1861.
- Gallant JE, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3 year randomized trial. JAMA. 2004;292:191–201.
- Gallant J, DeJesus E, Arribas J, et al. The combination of tenofovir disoproxyl fumarate, emtricitabine and efavirenz produces superior outcomes compared to fixed dose zid-ovudine-lamivudine and efavirenz in antiretroviral-naive pa-tients (Study GS-934). N Enql J Med. 2006;354:251–260.
- Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865–1873.
- Sustiva Package Insert. Bristol Myers Squibb.
- Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection N Engl J Med. 2003;349:2304–2315.
- Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039–2046.
- Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir or stavudine. J Acquir Immune Defic Syndr 2006;43:284–292.
- US Food and Drug Administration. Guidance for industry: antiretroviral drugs using plasma HIV RNA levels-clinical considerations for accelerated and traditional approval. October 2002. Available at: http://www.fda.gov/Cder/guidance/3647fnl.htm
- Saag M, Cahn P, Raffi F, et al. Safety and efficacy of emtricitabine vs. stavudine in combination therapy in antiretroviral-ndive patients (Study FTC-301A). JAMA. 2004;292:180–190.
- Moyle G, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral naive HIV-infected adults (Study 30021). J Acquir Immune Defic Syndr 2005;38:417–425.
- DeJesus E, Herrera G, Tenfilo E, et al. Abacavir versus zid-ovudine plus lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults (Study 30024). Clin Infect Dis. 2004;39:1038–1046.
- DeJesus E, McCarty D, Farthing CF, et al. Once-daily ver-sus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39(3):411–418. Epub 2004 July 15.
- Squires K, Thiry A, Giordano M. Atazanvir (ATZ) QD and efavirenz (ER)) QD with fixed dose ZDV+3TC: a compari-son of antiviral efficacy and safety through week 24 (A1424-034). In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego, CA.
- Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiret-roviral-naïve patients: virologic, immunologic, and morpho-logic changes- a 96-week analysis. J Acquir Immune Defic Syndr 2006;43(5):535–540.
- Sanne I, van der Horst C, et al. Two randomized, controlled, equivalence trials of emtricitabine (FTC) to lamivudine (3TC). In: XIV International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Poster 4432.
- Riddler S, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, Pl- and NNRTI-spar-ing regimens for initial treatment of HIV-1 infection- ACTG 5142. In: Program and abstracts of the XVIth International AIDS Conference; August 13–18, 2006; Toronto, Canada. Abstract THLB 0204.